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Abstract
Aims: We evaluated the potential of a nanoparticle (NP) delivery system to
improve methods of delivery of candidate peptide-based vaccines for
Paratuberculosis in cattle.
Methods and Results: Peptides derived from Mycobacterium avium subsp.
paratuberculosis (Map), and the pro-inflammatory monophosphoryl lipid A
(MPLA) were incorporated in polymeric NPs based on poly (D,L-lactide-co-
glycolide) (PLGA). The PLGA/MPLA NPs carriers were incubated with
macrophages to examine their effects on survival and function. PLGA/MPLA
NPs, with and without Map antigens, are efficiently phagocytized by
macrophages with no evidence of toxicity. PLGA/MPLA NP formulations did
not alter the level of expression of MHC I or II molecules. Expression of TNFa
and IL12p40 was increased in Map-loaded NPs. T-cell proliferation studies
using a model peptide from Anaplasma marginale demonstrated that a CD4 T-
cell recall response could be elicited with macrophages pulsed with the peptide
encapsulated in the PLGA/MPLA NP.
Conclusions: These findings indicate PLGA/MPLA NPs can be used as a
vehicle for delivery and testing of candidate peptide-based vaccines.
Significance and Impact of the Study: These results will assist on more in
depth studies on PLGA NP delivery systems that may lead to the development
of a peptide-based vaccine for cattle.
Introduction
Paratuberculosis is a costly, chronic, progressive granulo-
matous disease of the small intestine of ruminants caused
by Mycobacterium avium subsp. paratuberculosis (Map),
with high prevalence in US dairy herds (Harris and Bar-
letta 2001). Control programmes for paratuberculosis
have been impeded by an incomplete understanding of
the immune response to Map and the lack of a vaccine
that induces protective immunity (Harris and Barletta
2001; Chen et al. 2012; Settles et al. 2014; Bannantine
and Talaat 2015). Attempts to develop more efficient vac-
cines against Map have not been successful (Bannantine
and Talaat 2015; Bannantine et al. 2014). Commercial
vaccines available for ruminants reduce production losses,
mortality, histopathological lesions (Wentink et al. 1994;
Griffin et al. 2009), bacterial shedding (Kormendy 1994)
and extend the productive life of vaccinated animals, but
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do not provide complete protection from infection (Red-
dacliff et al. 2006; Bannantine and Talaat 2015). More-
over, the use of a killed or live attenuated vaccine is
limited mainly to sheep due to the cross-reaction it pro-
duces with the immunological diagnosis of bovine tuber-
culosis in cattle (Stringer et al. 2011). The research
highlighted above emphasizes the need to explore devel-
opment and testing of new candidate vaccines for
efficacy.
Recent studies with a Map relA deletion mutant suggest
it might be possible to develop a peptide-based vaccine
(Park et al. 2014). Deletion of relA, a global gene regulator,
disrupts the capacity of Map to establish a persistent infec-
tion indicating that the response directed towards one or
more Map proteins is sufficient to block the establishment
of a persistent infection. Identification of which proteins
account for blocking development of persistent infection
could lead to the development of a peptide-based vaccine.
Such a vaccine would clearly have advantages over killed
and live attenuated mutant vaccines in terms of feasibility
for large-scale commercial production, and human safety.
As mentioned, one of the impediments in developing pep-
tide-based vaccines has been identifying a delivery system
that protects and optimizes delivery of peptides to antigen
presenting cells (APC) through pattern recognition recep-
tors (PRRs) that modulate the expression of cytokines that
drive differentiation of T cells with different effector activ-
ity. The objective of the present study was to evaluate a
novel delivery system for its potential use in next-genera-
tion vaccines for Paratuberculosis, and other pathogens
affecting the livestock industry.
Poly lactic-co-glycolic acid (PLGA) is a safety polymer
with diverse formulations available commercially and
approved by health regulatory agencies (Danhier et al.
2012). PLGA NPs have been shown to boost immune
responses in several animal models (Elamanchili et al.
2007; Klippstein and Pozo 2010; Hamdy et al. 2011; Dan-
hier et al. 2012). For example, enhanced immune
responses to entrapped antigens were observed in mice
following oral administration of PLGA NPs. These find-
ings were considered to be a consequence of their uptake
into M cells, and their ability to stimulate APC in Peyer’s
patches in the intestines (Eldridge et al. 1992). PLGA
NPs polarize immune responses from predominantly
antibody- and Th2-type responses to the more protective
Th1-type responses (Conway et al. 2001), and also facili-
tate the induction of CD8 cytotoxic T lymphocytes in
several disease models (Conway et al. 2001; Chong et al.
2005; Elamanchili et al. 2007). Depending on the goal, an
extensive variety of particle sizes with unique physico-
chemical characteristics, antigen load and release profiles
can be formulated using PLGA. Studies have shown that
300 nm to 2 lm NPs are readily phagocytized by
macrophages (Elamanchili et al. 2007; Hamdy et al. 2011;
Danhier et al. 2012). Importantly, as biochemically dis-
tinct molecules can be encapsulated in PLGA NPs, a wide
variety of adjuvants can be incorporated in the same
PLGA NP formulation, thereby increasing the effective-
ness of the vaccine (Chong et al. 2005; Elamanchili et al.
2007; Klippstein and Pozo 2010; Hamdy et al. 2011).
Monophosphoryl lipid A (MPLA) is a commercially
available endotoxin derivative that has been used as a vac-
cine adjuvant (Ulrich and Myers 1995; Kathaperumal et al.
2008; Fichter et al. 2015). MPLA is produced by the
hydrolysis of native diphosphoryl lipid A, the component
of LPS that is recognized specifically by the pro-inflamma-
tory receptor TLR4 (Wang 2013). The structural alterations
that occur during this process (i.e. removal of all but a sin-
gle phosphate group; deacylation) decrease systemic toxic-
ity by >99% when compared to native bacterial LPS. This
results in an immunomodulatory agent with greater poten-
tial for clinical use (Wang 2013; Cui et al. 2014; Fichter
et al. 2015). The attenuated toxicity of MPLA is associated
with reduced induction of pro-inflammatory cytokines
such as TNFa, IL1b and IFNc during initial exposure.
Despite this, MPLA retains significant immunomodulatory
activity and prior treatment with MPLA increases survival
after otherwise lethal exposure to LPS in animal models
(Wang 2013; Cui et al. 2014; Fichter et al. 2015).
One question that had to be addressed at the outset of
this study was which Map protein should be encapsulated
into the NPs. We restricted our selection to lipoproteins
because they have been shown to interact with the TLR2
pathway (Noss et al. 2001; Bowdish et al. 2009). By mea-
suring cytokine proliferation in response to 42 Map
lipoproteins, we identified two protein candidates
(MAP2322c and MAP0981c) that induced high levels of
the immune-modulatory cytokine IL12 and the pro-
inflammatory cytokine TNFa, while inducing low levels of
the anti-inflammatory protein IL10 (Bannantine et al.
2015). These two proteins were incorporated into NPs for
this study.
As described herein, examination of the methods of
construction and functional activity of MPLA/PLGA NP
as vectors for delivery of peptide-based vaccines have
shown PLGA NPs are a good choice as a delivery system
for peptide-based vaccines for Paratuberculosis, Anaplas-
mosis and other pathogens of ruminants.
Materials and methods
Bovine monocyte isolation and in vitro macrophage
generation
The study was carried out in accordance with the recom-
mendations, institutional guidelines and approved Animal
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Care and Use Committee (IACUC) protocols (#04543-
003) at Washington State University. Peripheral blood
used for monocyte isolation were collected from healthy
adult Holstein dairy cows that tested negative for paratu-
berculosis as determined by faecal culture and polymerase
chain reaction (PCR) assays of blood and faecal samples.
Isolation and generation of bovine macrophages was car-
ried out as previously described (Souza 2015). Briefly,
peripheral blood mononuclear cells (PBMC) were isolated
by centrifugation on a Percoll (Sigma-Aldrich, St. Louis,
MO, USA) density gradient. Briefly, blood was layered
onto 50-ml conical tubes containing Histopaque 1077
(Sigma-Aldrich), and following density gradient centrifu-
gation (500 g for 20 min) at room temperature, PBMC
were collected. The PBMC were washed twice with sterile
phosphate-buffered saline (PBS; Invitrogen™; Thermo-
Fisher Scientific, Waltham, MA, USA) before being resus-
pended in PBS. Monocytes were then isolated using
microbeads conjugated to a cross-reactive mouse anti-
human CD14 Mab (Miltenyi Biotec Ltd, San Diego, CA).
The isolation was performed according to the manufac-
turers’ instructions. The identity and purity of monocytes
was >95% as determined by flow cytometry using an
anti-CD14 fluorescein-labelled antibody as described
(Souza 2015). Purified monocytes were seeded at 1 9 106
per well on standard 24-well tissue culture plates contain-
ing RPMI 1640 medium (Invitrogen, Life Technologies
Corporation) containing 10% heat-inactivated FBS
(Sigma-Aldrich), gentamicin (5 g l1; Sigma-Aldrich),
100 lg l1 of bovine-specific GM-CSF (Kingfisher, St.
Paul, MN, USA) and 1 mol l1 b-mercaptoethanol. Sub-
sequently, cells were incubated at 37°C and 5% CO2. On
Day 7, confluent monolayers of MoMΦ displayed the
characteristic macrophage morphology as confirmed by
light microscopy and expected immunophenotype. There-
after, MoMΦ were used for the in vitro challenge
experiments with PLGA NPs formulations.
Production and purification of recombinant Map
proteins
Recent evidence suggests that Map proteins play key roles
in the host-immune responses to Map (Souza et al.
2013), and many vaccine trial studies using Map proteins
as immunogens have shown promise (Rigden et al. 2006;
Kathaperumal et al. 2008, 2009; Roupie et al. 2008). We
therefore screened a large number of Map proteins anno-
tated as lipoproteins to test in our in vitro macrophage
model. These proteins were recombinantly expressed in
Escherichia coli and purified by affinity chromatography
(Bannantine et al. 2015). Briefly, Map genes annotated as
lipoproteins (MAP2322c and MAP0981c), along with sev-
eral control proteins were cloned into the pMAL-c2x
expression vector and transformed into E. coli DH5. All
clones were confirmed to be correct and in-frame with
the maltose-binding protein by DNA sequencing. Con-
firmed transformants were cultured, induced with iso-
propyl b-D-1-thiogalactopyranoside (IPTG), and purified
as described previously (Bannantine et al. 2010). The only
modification was that proteins eluted off the amylose
resin column were collected and loaded onto a second
amylose column to maximize removal of potential LPS
contamination. These proteins were expected to be non-
lipidated and were used for the PLGA NP synthesis.
Synthesis of PLGA NP formulations
PLGA NPs were formulated to internally carry one of five
different proteins at 10% w/v: MAP0981c, MAP2322c,
OVA, OVA-FITC or Anaplasma marginale outer mem-
brane (OM)-derived peptides, VirB9-2 P5, or VirB9-1 P8
(which were gifts from Dr Brown, Washington State
University. Externally PLGA NPs were loaded with MPLA
at 1% w/v. PLGA NPs were generated using the double
emulsion water-in-oil-in-water (w/o/w) technique as pre-
viously described by our group (Guldner et al. 2016a).
Briefly, 9 g l1 of PLGA 75:25 (PolySciTech, IN) at a
molecular weight of 25–35 kDa were dissolved in 450 ll of
chloroform; 50 ll of PBS was then added to create a
water-in-oil (w/o) emulsion. The resultant solution was
emulsified by sonication twice for 30 s each on ice using a
Branson Ultrasonics Sonifier™ Cup Horn sonicator at an
amplitude of 20%. This first emulsion was then added
dropwise into 1 ml of 1% poly vinyl alcohol (PVA) (Sigma
Aldrich, St. Louis, MO, USA) at a molecular weight of 31–
50 kDa, while the mixture was being continuously vor-
texed. Initially, 25 ml of a PLGA chloroform solution
(60 g l1) was mixed with 01 ml of a MPLA from S. Min-
nesota R595-TLR-based adjuvant vaccine grade™ (Invivo-
Gen, San Diego, CA) solution (20 g l1) in methanol:
chloroform (1 : 4 v/v). Emulsion (w/o) was carry out by
adding 05 ml of 20 g l1 of the several peptides used in
this study adjusted for the required concentration into the
PLGA/MPLA recipe. A bath sonicator (Vibra Cell VC-505)
at a 40% amplitude for 40 s was used for the emulsifica-
tion step. Then, the emulsion (w/o) was added into a
12 ml, 1% w/v PVA solution. The recipe was then soni-
cated at a 40% amplitude for 2 min. The resulting emul-
sion was vortex overnight for proper solvent evaporation.
The PLGA NPs were purified by means of four successive
centrifugations at 5000 g and 4°C for 10-min dispersion
cycles, and were subsequently lyophilized. Empty and
PLGA/MPLA NPs served as controls. PLGA NPs were then
dispersed in a 9% (w/v) sucrose solution (10 g l1 NP per
ml sucrose solution) followed by sterilization in a UV
incubator for 10 min to 20 min.
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Determination of PLGA NP morphology
The morphology of the PLGA NPs was determined by
scanning electron microscopy (SEM). Briefly, dried PLGA/
MPLA preparations containing MAP2322c, MAP0981c or
LPS-free OVA were applied onto a pin stub covered with
double-sided carbon tape and then coated with 35 nm of
platinum/palladium using a Cressington Sputter Coater.
Images were taken using an FEI Quanta 200F SEM (Fran-
ceschi Microscopy and Imaging Center, WSU, Pullman,
WA) at 5–10 kV accelerating voltage. The PLGA NPs
preparation sizes were then measured using ImageJ soft-
ware (NIH, Bethesda, MD, USA, 148v).
Determination of PLGA NPs polydispersibility and zeta
potential
Polydispersibility and zeta potential were performed using
Zetasizer nano ZS instrument and DTS software (Malvern
Instruments, Worcestershire, UK). Briefly, the lyophilized
PLGA NPs formulations contained in microcentrifuge
tubes were suspended in PBS, pH 74 and introduced
into the instrument according to manufacture guidelines.
Determination of MAP0981c, MAP2322c, OVA and
MPLA encapsulation efficiency
A protein assay kit (Pierce Biotechnology, Rockford, IL)
was used for the quantification of protein loading in NP
preparations (wt%). Briefly, 25 g l1 of PLGA NPs were
dissolved in 02 ml of 01 mol l1 NaOH solution. After
overnight incubation at 4°C, the protein concentration
was measured using a BCA protein assay kit according to
the manufacturer’s instructions. Sample absorbance was
measured at 562 nm by means of a microplate reader
(BioTek, Winooski, VT). Empty PLGA NPs served as the
control. Protein encapsulation efficiency (EE) is deter-
mined as the ratio of the protein content in the PLGA
NPs divided by the total mass of protein used. A limulus
amebocyte lysate (LAL) kit (ThermoFisher Scientific,
Rockford, IL, USA) was used for the determination of
the MPLA LC (wt%) in the NPs. Accordingly, aqueous
MPLA solutions were analysed with LAL in a plate reader
to set up a calibration curve. The calibration curve for
the MPLA concentration ranged from 001 to 10 lg l1
with a calculated correlation coefficient of R2 = 09.
MPLA content in the PLGA NPs was calculated by sub-
tracting the concentration of supernatant-containing
MPLA from the starting concentration of MPLA in the
formula. MPLA EE was determined by the ratio of the
measured MPLA concentration in the PLGA NPs to the
total concentration of MPLA in the formula.
Intracellular uptake of PLGA NP preparations by bovine
macrophages
MoMΦ were incubated with 50 mg l1 PLGA/MPLA
alone or PLGA/MPLA NP containing LPS-free OVA-
FITC (EndoFit™; InvivoGen) for 24 h. The cells were
detached from the 12-well plates after a 10 min-incuba-
tion at 37°C with a prewarmed solution of 10 mol l1
EDTA containing 5% FBS. After two washes, the cells
were fixed with 2% paraformaldehyde containing 2% glu-
taraldehyde in 01 mol l1 PBS overnight at 4°C. MoMΦ
were dehydrated with ethanol: acetone solution and
embedded in resin. Sections were realized via a micro-
tome (Leica Reichert Ultracut R Microtome, Franceschi
Microscopy and Imaging Center, WSU). The sections
were then placed on a nickel grid, followed by staining
with 2% aqueous uranyl acetate. Analysis of the uptake
of PLGA/MPLA OVA-FITC NPs by MoMΦ was per-
formed by transmission electron microscopy (TEM) (FEI
Tecnai G2 20 Twin, Franceschi Microscopy and Imaging
Center) at 200 kV.
Cellular uptake of PLGA/MPLA OVA-FITC NP was
subsequently evaluated by confocal microscopy (Zeiss 510
META Confocal Laser Scanning Microscope, Franceschi
Microscopy and Imaging Center). Briefly, MoMΦ were
cultured on coverslips in a six-well culture plastic plate
and then incubated for 2 h with 50 mg l1 of PLGA NPs
formulations as described above. After cell culture med-
ium removal, the cells were fixed with 2% paraformalde-
hyde for 10 min at 37°C. The coverslips were rinsed with
PBS and stained with a drop of ProLong Gold antifade
reagent with DAPI (40,6-diamidino-2-phenylindole) and
evaluated by confocal microscopy. DAPI was excited with
a diode laser (405 nm) and the emission was collected
with a BP420-480 IR filter. FITC was excited with an
argon laser at 488 nm and the emission was collected
with BP505-570 IR filter. Multitracking was used to
decrease interchannel cross-talk and confocal scanning
parameters were set up for bright field background.
Further evaluation of phagocytosis was performed by
flow cytometric analysis. Briefly, after 7 days of culture,
1 9 106 MoMΦ per ml were treated with either PBS,
50 mg l1 OVA-FITC or PLGA/MPLA OVA-FITC NP
for 24 h. Four wells of a standard 12-well plastic culture
plate were assigned to each of these treatment groups.
The cells were harvested using a sterile cell scraper, and
thoroughly washed using PBS at 37°C to remove non-
phagocytized PLGA NPs. Samples were analysed on a BD
FACSCalibur and analysed using FCS Express 4 (DeNovo
Software, Los Angeles, CA). Results were presented as
histograms, with the macrophages incubated with PBS
and an isotype Mab as a control for nonspecific binding.
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Viability of bovine macrophage exposed to PLGA NP
preparations
MoMΦ viability was evaluated by trypan blue exclusion
assay and morphology by light microscopy. MoMΦ were
incubated with 50 mg l1 of PLGA/MPLA NPs,
50 mg l1 of PLGA/MPLA/MAP0981c or 50 mg l1 of
PLGA/MPLA/MAP2322c NPs for 2 or 24 h. The adherent
cells were harvested after incubation at 37°C with pre-
warmed solution of 10 mol l1 EDTA in 5% PBS and
mixed with trypan blue (1 : 10). The percentage of viable
MoMΦ (cells that did not take up trypan blue), was
assessed in a haemocytometer chamber using light micro-
scopy. Aliquots of 1 9 106 MoMΦ were further cytocen-
trifuged at 4000 g for 5 min (Cytospin™; ThermoFisher,
Waltham, MA), and stained with a Wright’s-based stain.
Thereafter, macrophage morphology was evaluated by
light microscopy for evidence of apoptosis or cell necrosis
by a Board Certified Clinical Pathologist.
Determination of TNFa, IL12p40 and IL10 expression
by qRT-PCR
Seven-day-old bovine MoMΦ were incubated with
50 mg l1 of PLGA/MPLA NPs, 50 mg l1 of PLGA/
MPLA/MAP0981c, 50 mg l1 of PLGA/MPLA/MAP2322c
NPs or 1 mg l1 of LPS for 0, 24, 36 or 72 h. Total RNA
was extracted from the treated cells using the Aurum™
Total RNA Mini Kit (BioRad, Hercules, CA) following
the manufacturer’s recommendations for cultured cells.
The amount of total RNA was determined spectrophoto-
metrically (NanoDrop™ 1000 Spectrophotometer;
Thermo Scientific, Waltham, MA). Reverse transcription
of mRNA into cDNA was processed in accordance with
the manufacturer’s recommendations (iScriptTM Reverse
Transcription Supermix for RT-qPCR; BioRad, Hercules,
CA) to obtain a cDNA final volume of 20 ll from
100 ng of total RNA using a thermal cycler (Axygen
MaxyGeneTM II Thermal Cycler, Corning, NY). The
cDNA product was amplified by PCR using validated pri-
mers designed by Qiagen RT2 qPCR Primer Assay as
described (Souza 2015). Expression levels of GAPDH
gene were used to normalize the input of cDNA. Real-
time PCR was performed using Power SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA), fol-
lowing the manufacturer’s recommendations. Briefly,
each well contained a 20-ll reaction mixture consisting
of 10 ll of the SYBR Green qPCR Master Mix, 4 ll of
water, 2 ll of each specific primer set and 4 ll of 1/20
diluted cDNA template. The thermal profile settings con-
sisted of a 10-min denaturation at 95°C, 40 cycles of 15 s
at 95°C and 1 min at 60°C and a dissociation stage at
the end of the run from 60 to 95°C with 03°C
increments, and were carried out in a StepOnePlus™
Real-Time PCR system (Applied Biosystems). At least
two replicates of each product to verify for accuracy and
a nontemplate control to test for contamination of assay
reagents were included in each experiment. The relative
quantity of target, normalized to an endogenous control
and relative to a reference sample, was calculated based
on the threshold cycle (Ct) value of 2DDCT using Ste-
pOne™ software (ver. 2.3).
Immunophenotypic analysis of bovine macrophages
incubated with PLGA NP preparations
For a 24-h period prior to collection, 1 9 106 MoMΦ in
1 ml were incubated with PBS, 50 mg l1 of PLGA/
MPLA NPs and 50 lg ml1 PLGA/MPLA/MAP2322c NP
in individual standard wells of a 12-well plastic culture
plate. Three to four wells were assigned to each of the
aforementioned study groups. The macrophages treated
with PBS were utilized as a control. The cells were col-
lected using a sterile cell scraper, and gently washed using
PBS at 37°C. For phenotypic maturation studies, the
MoMΦ of each group were separately incubated with
15 mg l1 of COLIS69A (Mab isotype control with speci-
ficity for E. coli J5), major histocompatibility complex
(MHC) I (clone H6A) and MHC II (clone CAT82A), fol-
lowed by incubation with a fluorescein-conjugated IgG/
IgM antibody. All Mabs were obtained from the Wash-
ington State University Monoclonal Antibody Center,
Pullman, WA. Samples were acquired on a Becton Dick-
inson FACSCalibur (BD Biosciences, Franklin Lakes, NJ)
by gating on the live cell populations. All non-CD14+
populations were excluded. The data were further evalu-
ated using FCS Express 4 (DeNovo Software) and pre-
sented as dot plots.
CD4T Cell proliferation assay
Blood was collected from calf 48432 (DRB3*1101/*1401)
that was previously immunized four times subcutaneously
at 3-week intervals with 60 lg of purified A. marginale
St. Maries strain OMs (Lopez et al. 2005) emulsified in
6 mg of saponin diluted in 13 ml PBS. PBMC were puri-
fied from blood samples by Histopaque gradient centrifu-
gation, repeatedly washed with Hanks’ buffered salt
solution (ThermoFisher Scientific, Waltham, MA), sus-
pended in RPMI 1640 medium (Sigma-Aldrich) supple-
mented with 10% FBS, 100 mmol l1 L-glutamine,
50 mol l1 2-ME, 24 mmmol l1 HEPES buffer, and
50 mg l1 gentamycin sulphate (complete RPMI;
cRPMI). To establish 2-week T-cell lines, 4 9 106 PBMC
were cultured in 15 ml cRPMI with 1 mg l1 A. margin-
ale OM in 24-well plates and incubated in 5% CO2 at
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37°C for 1 week allowing an enrichment of OM-specific
T cells. T cells were collected, washed and resuspended in
cRPMI, and cultured in 24-well plates at 7 9 105 cells
per well with 2 9 106 cells per well of irradiated (3000
rads) autologous PBMC as a source of APC without anti-
gen (rested) for 1 week in 5% CO2 at 37°C. Cells were
then centrifuged, washed, and resuspended in cRPMI.
3 9 104 T cells and 2 9 105 irradiated PBMC were cul-
tured in a total volume of 100 ll in 96-well round-bot-
tomed plates. Anaplasma marginale OM-derived peptides
VirB9-1 P8 (negative control) and VirB9-2 P5 were tested
at 1 mg l1 and 10 mg l1. NP formulations PLGA/
MPLA (control), PLGA/MPLA/VirB9-1 P8, and PLGA/
MPLA/VirB9-2 P5 were tested at 5 and 25 mg l1 NP.
For all assays, cells with medium only served as a nega-
tive control and cells with 10% T-cell growth factor
(TCGF) served as a positive control. Cells were incubated
in 5% CO2 at 37°C for 3 days, radiolabelled with
025 lCi 3H-thymidine per well and incubated an addi-
tional 18 h before harvesting with a Tomtec Harvester96
and quantifying with a PerkinElmer 1450 TriLux
MicroBeta liquid scintillation counter (Waltham, MA,
USA). Results are presented as the Stimulation Index, cal-
culated as the mean CPM of cells cultured with antigen/
mean CPM of cells cultured with medium.
Statistical analysis
The experiments were run in biological triplicates. A two-
tailed paired t-test was used to compare two data. Values
of P < 005 were considered statistically significant.
Results
Characterization of PLGA NP formulations
Physical–chemical characterization, including hydrody-
namic diameter, zeta potential, Polydispersity Index,
mobility, conductivity and encapsulating efficiency (EE)
of peptides and MPLA, of the several PLGA NPs
constructs used in this study are summarized in Table 1.
The mean diameters of PLGA varied from 431 to
1218 nm. Zeta potential showed negative values for all
NP preparations (858 to 148 mV). PLGA/MPLA NP
showed reduced overall surface negativity except for
PLGA/MPLA/MAP2322c. The results described herein
suggest negligible differences among the PLGA NPs
preparations used in this study. The EE for the PLGA
NPs preparation varied from approximately 50–100%.
Higher EE were also obtained for preparation containing
MPLA with exception of the PLGA/MPLA/MAP2322c.
SEM of the PLGA/MPLA/Map peptide and Ova NPs
showed that the NPs were spherical, presenting with
smooth surface with absence of superficial irregularities
containing an electron dense core when peptides were
present. A representative example is shown in Fig. 1a,b.
The in vitro release of PLGA/MPLA/MAP0981c and
PLGA/MPLA/Ova NP in PBS at 37°C was evaluated over
4 weeks. Results indicated that ~30% of MAP0981c is
released from PLGA/MPLA NPs during the first week
reaching at maximum a released profile of ~60% after
4 weeks (data not shown). The obtained results were in
agreement with those previously reported in the literature
for the same PLGA NPs under similar conditions (Sarti
et al. 2011; Danhier et al. 2012; Guldner et al. 2016a).
PLGA NP uptake by bovine macrophages
Uptake of the PLGA NP preparations by bovine MoMΦ
was evaluated by flow cytometry, confocal microscopy
and TEM. Only PLGA/MPLA preparations containing
OVA-FITC were used for the confocal and flow cytome-
try experiments. Bovine MoMΦ were incubated with
PLGA/MPLA/OVA-FITC for 24 h and mean fluorescent
intensity (MFI) of FITC was measured by flow cytometry
against macrophages incubated with PBS or OVA-FITC
(i.e. positive control). Results showed that PLGA/MPLA
NPs were efficiently internalized by MoMΦ (Fig. 2g,h).
These observations were consistent with previous studies
performed on the ability of APCs to efficiently
Table 1 Properties of PLGA NPs constructs used in this study
Formulation
Hydrodynamic
diameter (nm)
Zeta Potential
(mV)
Polydispersity
Index
Mobility
(lmcm Vs1)
Conductivity
(mS cm1)
Protein
EE (%)
MPLA
EE (%)
PLGA 431 SD  162 148 0141 1159 18 – –
PLGA/OVA 6581 SD  2737 113 0518 0885 19 100 –
PLGA/MPLA 400 SD  125 858 0947 0672 18 – 9841
PLGA/MPLA/OVA 5667 SD  3393 941 0358 0737 18 908 9734
PLGA/MPLA/0981c 1218 SD  118 858 0947 0672 18 1085 689
PLGA/MPLA/2322c 7647 SD  6285 114 0675 0896 18 5013 372
EE, encapsulation efficiency; PLGA, poly (lactic-co-glycolic acid); MPLA, monophosphoryl lipid A; OVA, ovalbumin; 0981c and 2322c, MAP recom-
binant peptides.
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phagocytize PLGA NPs (Keijzer et al. 2011, 2013; Danhier
et al. 2012). TEM studies demonstrated that MoMΦ
incubated with PLGA/MPLA NPs containing OVA or
MAP0981c for 24 h displayed several electron dense
intracytoplasmic structures compared to the control (i.e.
PBS alone, data not shown), consistent with
internalization of the PLGA NPs (Fig. 2e,f). In addition
to flow cytometry and TEM, the cellular localization of
PLGA NPs was assessed by confocal microscopy and
showed efficient uptake of NPs (Fig. 2a–d). Comparable
results were obtained when PLGA without MPLA NPs
were used (data not shown), suggesting that MPLA had
Peptide
antigen MPLA
PLGA
(a) (b)
Figure 1 Morphological characterization of PLGA/MPLA NP. (a) Morphological analysis of PLGA/MPLA NP by scanning electron microscopy
(SEM). (b) Transmission electron microscopy (TEM) of a single PLGA/MPLA/peptide NP. Scale bar = 1 lm (a) and 100 nm (b). PLGA, poly lactic-
co-glycolic acid; MPLA, monophosphoryl lipid A.
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Figure 2 Cellular localization of PLGA/MPLA/OVA-FITC NPs uptake by macrophages and evaluated by confocal laser scanning microscopy after
2 h of incubation. Day 7 bovine MoMΦ cultures (1 9 106) were incubated with 50 mg l1 of PLGA/MPLA/OVA-FITC NPs. After 24 h, MoMΦ
were harvested and analysed by confocal microscopy. One representative experiment is shown. (a) Nucleus of macrophages stain blue by DAPI.
(b) PLGA/MPLA/OVA-FITC NPs stain green. (c) Bovine MoMΦ observed by phase contrast microscopy. (d) Merge of (a) and (b) demonstrating
internalization of NPs. Scale bar = 5 lm. DAPI = 40,6-diamidino-2-phenylindole, dihydrochloride; FITC, fluorescein isothiocyanate. Transmission
electron microscopy (TEM) evaluation of cellular uptake of PLGA/MPLA NP preparations by bovine macrophages. Day 7 bovine MoMΦ cultures
(1 9 106) were incubated with PBS or 50 mg l1 of PLGA/MPLA/MAP0981c NPs. After 24 h, nonadherent cells were harvested and analysed by
TEM. (e, f) MoMΦ incubated with PLGA/MPLA/Map0981c NPs for 24 h showing PLGA/MPLA NPs within phagocytic vacuoles (*). Flow cytometric
evaluation of cellular uptake of PLGA NP preparations by bovine MoMΦ. Flow cytometric analysis of MoMΦ treated with PLGA/MPLA/OVA-FITC
NPs. MoMΦ cultures (1 9 106) were incubated with 50 mg l1 of PLGA/MPLA/OVA-FITC NP or OVA-FITC. After 24 h, nonadherent cells were
harvested and analysed by flow cytometry. One representative experiment is shown. (g) Mean fluorescence intensity (MFI) of MoMΦ incubated
with 50 mg l1 OVA-FIT for 24 h. (h) MFI of MoMΦ incubated with 50 mg l1 PLGA/MPLA/OVA-FITC for 24 h. [Colour figure can be viewed at
wileyonlinelibrary.com]
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no effect on the ability of bovine MoMΦ to phagocytize
the PLGA NPs formulations used in this study.
Macrophage viability studies
MoMΦ viability was evaluated by incubating 7-day-old
bovine MoMΦ with PLGA/MPLA, PLGA/MPLA/
MAP0981c and PLGA/MPLA/MAP2322c NPs for 2 or
24 h. The results showed that there were no significant
differences between the control groups and the several
PLGA NPs tested at 2 or 24 h postincubation (Fig. 3a).
In addition, cultures of MoMΦ incubated with different
PLGA NPs constructs for 24 h and evaluated by light
microscopy by a Board Certified Clinical Pathologist
demonstrated absence of abnormal cytomorphological
features consistent with cell death (i.e. apoptosis and
necrosis; Fig. 3b). Lack of toxicity of PLGA NPs with or
without MPLA to APCs was expected and corroborate
with studies performed previously (Silva et al. 2015;
Guldner et al. 2016a). Daily visual evaluation of the
MoMΦ in culture for up to 5 days postviability analysis
did not demonstrate cytomorphological changes that
could be consistent with cell death. In addition, the RNA
concentration and its quality also did not change
throughout the set points we used for the experiments
used on this study (data not shown).
Cytokine expression
Pro-inflammatory and pro-immune cytokine production
by primed APCs are considered important components
of an effective immune response and thus, essential in
designing effective vaccines. In this study, pro-inflamma-
tory (i.e. TNFa), pro-immune (i.e. IL12p40) and
anti-inflammatory (i.e. IL10) cytokine expression were
measured to evaluate the potential of PLGA NP prepara-
tions to induce early, protective, immune responses initi-
ated by MoMΦ. Bovine MoMΦ were incubated with
different PLGA NP constructs and the expression of the
above cytokines was determined at different time points
(Fig. 4). As expected, incubation of MoMΦ with PLGA
NPs containing MPLA (i.e. LPS derivative), upregulated
TNFa expression at all time points in this study.
Increases of more than 10-fold compared to control were
observed. The results also showed that PLGA/MPLA with
or without addition of MAP0981c or MAP2322c upregu-
lated TNFa at comparative levels as bacterial LPS at early
time points. Surprisingly, this increase was significantly
higher than the one elicited by LPS at later time points,
particularly when Map antigens were included in the for-
mulations (Fig. 4a). Similar increases were seen with
IL12p40 expression at all time points studied when
macrophages were incubated with LPS or PLGA NPs
preparations with or without addition of MAP0981c or
MAP2322c (Fig. 4b). Importantly, expression of IL10 did
not appear to be significantly induced at later time points
by incubation of MoMΦ with any of the PLGA NP for-
mulations used in this study (Fig. 4c).
Analysis of MHC I and MHC II expression
Seven-day-old MoMΦ were stimulated with empty
PLGA/MPLA NP or PLGA/MPLA/MAP0981c NPs for
24 h and thereafter cells were evaluated by flow cytome-
try. Results showed no difference in the expression of
MHC I or II by bovine MoMΦ stimulated with the above
PLGA NPs (data not shown).
T-cell stimulation assay
As a proof of concept, to show that the PLGA/MPLA
NPs loaded with antigen could stimulate CD4 T cells, we
used T cells from a calf that had been previously
Figure 3 Evaluation of bovine macrophage viability incubated with
PLGA NP formulations. Day 7 bovine MoMΦ cultures (1 9 106) were
incubated with 50 mg l1 of different PLGA NP formulations for 2 h
or 24 h at 37°C. MoMΦ were then stained with Trypan Blue and
evaluated microscopically. (a) Cells that take the stain have impaired
membranes and are considered dead cells. (b) A total of Day 7
(1 9 106) MoMΦ were cytocentrifuged and evaluated under light
microscopy for evidence of pyknosis or cellular necrosis. Similar data
were obtained in three independent experiments. [Colour figure can
be viewed at wileyonlinelibrary.com]
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immunized with A. marginale OM expressing MHC II
DRB3 haplotype *1101, which was shown to respond to
peptide 5 of VirB9-2, but not peptide 8 of VirB9-1
(Morse et al. 2012). PLGA/MPLA NP were loaded with
each peptide (as described above) and tested with free
peptide in a proliferation assay using a short-term T-cell
line, started from PBMC stimulated with OM for 1 week
and rested with APC without antigen for 1 week. The cell
line responded specifically and significantly to VirB9-2
P5, but not VirB9-1 P8 as predicted (Fig. 5). Importantly,
the T cells also responded specifically and significantly to
PLGA NPs loaded with VirB9-2 P5, but not with VirB9-1
P8 or empty PLGA/MPLA NPs. The response to VirB9-2
P5-loaded PLGA/MPLA NP was lower than the response
to free peptide VirB9-2 P5 as there is an estimated 10-
fold less peptide present in the PLGA NPs formulation.
Discussion
The objective of the present study was to evaluate the
potential of PLGA/MPLA NPs, as a vector system, for
delivery of candidate peptide-based vaccines for Paratu-
berculosis. Initial studies showed a modified double
emulsion solvent evaporation technique was the most
efficient method to prepare PLGA/MPLA NPs (Danhier
et al. 2012; Guldner et al. 2016a). Physicochemical analy-
sis of the PLGA/MPLA NP constructs in solution demon-
strated that NPs in solution were dispersed with limited
aggregation of particles. Examination by SEM showed
that PLGA NPs had a smooth regular surface in a size
range optimal for uptake by MoMΦ (Table 1) similar to
the size ranges observed in other studies (Elamanchili
et al. 2007; Kanchan and Panda 2007; Guldner et al.
2016b). Examination by TEM showed the PLGA/MPLA
NPs containing peptides were comprised of an outer ring
of MPLA and an inner ring of PLGA with a dense pep-
tide central core. Phagocytosis and viability studies
showed the PLGA NPs and PLGA/MPLA NPs were taken
up rapidly and efficiently with no evidence of cytotoxicity
at the concentrations used in the studies. Similar to pre-
vious reports, phagocytosis of the PLGA/MPLA NPs
increased the expression of TNFa and IL12p40. Flow
Figure 4 Effects of incubation of PLGA NP preparations on TNFa (a), IL12p40 (b) and IL10 (c), gene expression by bovine MoMΦ. Day 7 MoMΦ
(1 9 106 per mL) were pretreated with 50 mg l1 of PLGA/MPLA NP, PLGA/MPLA/MAP0981c NP, PLGA/MPLA/MAP2322c NP or LPS (1 mg l1)
for 0, 24, 48 or 72 h. GAPDH was used to normalize the results. *Statistically significant difference when compared to PBS and PLGA/MPLA NP-
treated group (P < 005). Similar data were obtained in three independent experiments. 0 h; 1 day; 3 day; 5 day.
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cytometric analysis of the level of expression of MHC I
and II molecules showed there was no clear change in the
level of expression of MHC I or MHC II molecules fol-
lowing uptake of PLGA/MPLA NPs with and without
inclusion of peptides (data not shown).
The last set of experiments were conducted for proof
of concept to show whether antigenic peptides processed
and presented by MoMΦ, pulsed with a peptide-contain-
ing PLGA/MPLA NPs can elicit a recall response ex vivo.
Ongoing studies of the immune response to A. marginale
with a steer (DRB3 haplotype *1101) had shown that a
MHC II-restricted response could be elicited to peptide 5
of VirB9-2, encoding an epitope recognized by CD4 T
cells. This afforded an unique opportunity to examine
the functionality of MoMΦ in a genetically defined con-
text with a source of autologous cells where experiments
could be duplicated as needed (Morse et al. 2012). A
control peptide, peptide 8 of the VirB9-1 protein had
been identified which is not recognized by the MHC II
allomorph expressed by the DRB3 haplotype *1101. Three
repeats of the experiment with a CD4 T-cell line specific
for peptide 5 of VirB9-2 demonstrated that MoMΦ
pulsed with encapsulated peptide 5 consistently elicited a
MHC II restricted immune response (Fig. 5).
The results obtained in the present study paves the way
for use of PLGA/MPLA NP technology to investigate meth-
ods for modulating the functional activity of APC by target-
ing the PRRs that initiate signalling cascades that drive T-
cell differentiation. The PLGA NPs have been shown to be
safe for use in vivo (Chong et al. 2005; Hamdy et al. 2011;
Silva et al. 2015; Guldner et al. 2016b). The present results
support they can also be used ex vivo, expanding opportuni-
ties for further studies of Anaplasmosis and especially for
ongoing studies focused on developing a peptide-based vac-
cine for Paratuberculosis. Ex vivo studies with monocyte-
derived dendritic cells (MoDC) and MoMΦ have shown
MoDC and MoMΦ pulsed with a relA deletion mutant elicit
a MHC-restricted recall response with PBMC from a steer
vaccinated with the mutant (Park et al. 2016). Analysis of
the response has shown both CD4 and CD8 T cells prolifer-
ate in response to antigens processed and presented to
PBMC by MoDC and MoMΦ. Of considerable interest, part
of the response is directed to another Map peptide under
consideration for inclusion in a peptide-based vaccine, a
major membrane protein (MMP) (Bannantine et al. 2003).
Preliminary studies comparing the proliferative response to
MMP alone and encapsulated in PLGA/MPLA have shown
that MoDC pulsed with PLGA/MPLA/MMP NP elicit a
more vigorous response than MoDC pulsed with MMP
alone (C. Souza et al. unpublished).
The need for more safe and effective vaccines has stimu-
lated the development of new vaccine technologies. These
include delivery systems and adjuvants to target the innate
immune system to provide a stimulus that potentiates the
development of antigen-specific immune responses. Deliv-
ery systems based on PLGA containing the immunomodu-
latory molecule MPLA has been shown to be safe and able
to elicit optimal immune responses. Moreover, they can be
administered by several routes, which offer the possibility
of developing both mucosal and systemic immune
responses. Our preliminary studies in bovine set the stage
for more in depth studies on NP delivery systems in a set-
ting that may lead to the development of a peptide-based
vaccine for economically important diseases of cattle. It will
be possible to conduct studies to detail how the delivery of
antigens to specific PRRs with PLGA/MPLA NPs modulate
the signalling cascades in APC that drive T-cell differentia-
tion. In addition, it will be possible to identify the peptide
sequences presented by MHC I as well as MHC II molecules
involved in T-cell activation and differentiation.
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